<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812418</url>
  </required_header>
  <id_info>
    <org_study_id>Pil-Clin-Noct-020</org_study_id>
    <nct_id>NCT04812418</nct_id>
  </id_info>
  <brief_title>Evaluation of a Combination of Plants in Anxiety-related Sleep Disorders: Randomized Trial Versus Placebo</brief_title>
  <official_title>Evaluation of a Combination of Plants in Anxiety-related Sleep Disorders: Randomized Trial Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larena SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this double-blind randomized clinical trial is to compare the effects of a&#xD;
      dietary supplement based on eschscholtzia and valerian extracts to a placebo after 28 days of&#xD;
      supplementation, in subjects suffering from sleep troubles associated with anxiety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep disorder severity</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of Insomnia Severity Index (ISI) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep disorder severity over time</measure>
    <time_frame>Baseline and D49 (end of follow-up)</time_frame>
    <description>Change from baseline of Insomnia Severity Index (ISI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of sleep disorder symptoms severity</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of Clinical Global Impression Severity (CGI-S) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of sleep disorder symptoms improvement</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of Clinical Global Impression Improvement (CGI-I) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of sleep disorder symptoms improvement after intervention</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of Patient Global Impression Improvement (PGI-I) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of Hamilton anxiety rating scale (HAM-A) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status over time</measure>
    <time_frame>Baseline and D49 (end of follow-up)</time_frame>
    <description>Change from baseline of Hamilton anxiety rating scale (HAM-A) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-form 36 questionnaire (SF36)</measure>
    <time_frame>Baseline and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of SF36 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actimeters</measure>
    <time_frame>Baseline, D7, D14, D21 and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of the mean values obtained from actimeters recording during the 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electronic sleep diaries</measure>
    <time_frame>Baseline, D7, D14, D21 and D28 (end of supplementation)</time_frame>
    <description>Change from baseline of the mean values obtained from electronic sleep diaries during the 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of sleep troubles</measure>
    <time_frame>Baseline, D28 (end of supplementation) and D49 (end of follow-up)</time_frame>
    <description>Change from baseline of sleep troubles regarding changes in medical prescriptions, reason of changes and number of intercurrent medical visits for sleep disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction</measure>
    <time_frame>Baseline and D49 (end of follow-up)</time_frame>
    <description>Change from baseline of Addiction questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline D7, D14, D21, D28 (end of supplementation) and D49 (end of follow-up)</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Sleep Troubles Associated With Anxiety</condition>
  <arm_group>
    <arm_group_label>Group (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg of eschscholtzia extract and 50 mg of valerian extract by tablet, without support 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Noctesia</intervention_name>
    <description>3 tablets every day at bedtime with a large glass of water</description>
    <arm_group_label>Group (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 tablets every day at bedtime with a large glass of water</description>
    <arm_group_label>Group (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman or man, aged of 18 to 65 years;&#xD;
&#xD;
          -  In good general health as evidenced by medical history and physical examination;&#xD;
&#xD;
          -  Having at least 3 episodes of sleep disorders per week including one or more of the&#xD;
             following:&#xD;
&#xD;
               1. difficulty falling asleep or&#xD;
&#xD;
               2. difficulty staying asleep or&#xD;
&#xD;
               3. poor quality sleep&#xD;
&#xD;
               4. Waking up earlier than desired&#xD;
&#xD;
          -  The insufficient sleep duration and quality is coupled with a feeling of general&#xD;
             fatigue;&#xD;
&#xD;
          -  Sleep disorder last for more than 1 month;&#xD;
&#xD;
          -  Presenting moderate to severe sleep disorder in the past month (ISI ≥ 15);&#xD;
&#xD;
          -  With anxiety resulting in a HAM-A score &gt; 8 and &lt; 25;&#xD;
&#xD;
          -  For women of childbearing age (women of childbearing potential, pre-menopausal or&#xD;
             having postmenopausal amenorrhea of less than 12 months, and women who have not&#xD;
             undergone surgical sterilization):&#xD;
&#xD;
               1. Negative blood pregnancy test&#xD;
&#xD;
               2. Acceptance to use an effective method of contraception, established for at least&#xD;
                  1 month, and throughout the duration of the study;&#xD;
&#xD;
          -  Fluent French speaking;&#xD;
&#xD;
          -  Provision of signed and dated informed consent form;&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A score &gt; 10 on the ESS scale (that would correspond to serious hypersomnia);&#xD;
&#xD;
          -  Sleep disorders secondary to another health problem (sleep apnea syndrome,&#xD;
             narcolepsy-cataplexy, idiopathic hypersomnia, restless legs syndrome, chronic pain&#xD;
             syndrome, ...) or an environmental factor (noise, light ...) or socio-professional&#xD;
             (shift work, young child at home, people who are often jet lagged,… );&#xD;
&#xD;
          -  Severe psychiatric disorder or disease within 6 months before inclusion (depression,&#xD;
             bipolar disorder, severe anxiety, psychosis, schizophrenic disorders, dementia,…) or a&#xD;
             severe neurologic trouble (Alzheimer's, autism, Parkinson's disease, …);&#xD;
&#xD;
          -  Subjects presenting severe gastro-intestinal, hepatic, respiratory, kidney or&#xD;
             cardiovascular disorder or severe infection (e.g. HIV, hepatitis, …);&#xD;
&#xD;
          -  Acute or chronic somatic pathologies which can interfere with sleep: kidney cancer,&#xD;
             etc.;&#xD;
&#xD;
          -  Subjects with pre-menstrual syndrome or myasthenia gravis;&#xD;
&#xD;
          -  Subjects who drink more than 2 glasses of alcohol per day (&gt; 20g of alcohol per day)&#xD;
             or with exaggerated consumption of theine (≥ 1l per day) and caffeine-rich (≥ 800ml&#xD;
             per day) beverages and energy drink (≥ 330ml per day);&#xD;
&#xD;
          -  Smoker;&#xD;
&#xD;
          -  Subject consuming drugs and/or with historical drug addiction;&#xD;
&#xD;
          -  Under psychotropic treatment within the last month before screening (neuroleptic,&#xD;
             anxiolytic, antidepressant, hypnotic, sedative, …) or under current medication&#xD;
             treatment which may alter the waking state (for example: cortisone, dopamine,&#xD;
             amphetamine, antihistamines, beta-blockers, certain cough syrups, .…);&#xD;
&#xD;
          -  Volunteer with suicidal risk according to the investigator;&#xD;
&#xD;
          -  Under phytotherapy treatment or food supplement for sleep disorders within the last&#xD;
             month before screening;&#xD;
&#xD;
          -  Volunteer presenting current infection and/or fever;&#xD;
&#xD;
          -  Volunteer with medical history of stroke or head trauma;&#xD;
&#xD;
          -  Pregnant or lactating woman;&#xD;
&#xD;
          -  Known allergy or intolerance to one product component (valerian, eschscholtzia or&#xD;
             excipients);&#xD;
&#xD;
          -  Subjects having participated to another clinical trial (with an investigational&#xD;
             product) one month before the inclusion;&#xD;
&#xD;
          -  Subjects that present alterations of their cognitive functions that will interfere&#xD;
             with the comprehension of the study and procedures and/or with the completion of&#xD;
             questionnaires;&#xD;
&#xD;
          -  Vulnerable patient (deprived of liberty by judicial or administrative decision, under&#xD;
             guardianship, curatorship or safeguard of justice, …);&#xD;
&#xD;
          -  Pharmacological resistance to common hypnotic/sedative drugs;&#xD;
&#xD;
          -  Allergy/intolerance to the actimeter straps;&#xD;
&#xD;
          -  Recent (&lt; 1 month before the inclusion) change in lifestyle (food, body weight &gt; 5kg,&#xD;
             sport).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samira Ait Addellah</last_name>
    <phone>(0)1 45 51 78 77</phone>
    <email>s.aitabdellah@pileje.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique en Nutrition</name>
      <address>
        <city>Louvain-la-Neuve</city>
        <zip>B-1348</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Pachikian, PhD</last_name>
      <phone>01 047 93 05</phone>
      <phone_ext>0032</phone_ext>
      <email>barbara.pachikian@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Sylvie Copine, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

